SYROS PHARMACEUMATICALS INC
Syros Pharmaceuticals, Inc. is a
biopharmaceutical company. The Company offers a
gene control platform designed to
analyze the
unexploited region of
deoxyribonucleic acid (DNA) in
human disease tissue to identify and drug targets linked to
genomically defined patient populations. The Company is focused on
developing treatments for cancer and
immune-mediated diseases and is building a pipeline of
gene control medicines. The Company's drug programs include
SY-1425 (retinoic acid receptor alpha (RARa) agonist) and
SY-1365 (cyclin-dependent kinase 7 (CDK7) inhibitor).
SY-1425 (tamibarotene) is an
oral,
potent and
selective agonist, or activator, of the
transcription factor RARa.
SY-1365 is a
small molecule inhibitor of the
transcriptional kinase known as
CDK7. The Company is using its platform to analyze
gene expression programs across
additional cancers,
solid tumors,
inflammatory diseases and
other diseases to find
optimal points of
therapeutic intervention in patients.
Day Range Sell:7.90-8.29
Douyu International Holdings Ltd
DOUYU INTERNATIONAL HOLDINGS LIMITED is a China-based company principally engaged in
...